Literature DB >> 22827750

Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010.

Walter H B Demczuk1, Irene Martin, Averil Griffith, Brigitte Lefebvre, Allison McGeer, Amanda Shane, George G Zhanel, Gregory J Tyrrell, Matthew W Gilmour.   

Abstract

A baseline serotype distribution was established by age and region for 2058 invasive Streptococcus pneumoniae isolates collected during the implementation period of the 13-valent pneumococcal conjugate vaccine (PCV13) program in many parts of Canada in 2010. Serotypes 19A, 7F, and 3 were the most prevalent in all age groups, accounting for 57% in <2 year olds, 62% in 2-4 year olds, 45% in 5-14 year olds, 44% in 15-49 year olds, 41% in 50-64 year olds, and 36% in ≥65 year olds. Serotype 19A was most predominant in Western and Central Canada representing 15% and 22%, respectively, of the isolates from those regions, whereas 7F was most common in Eastern Canada with 20% of the isolates. Other prevalent serotypes include 15A, 23B, 12F, 22F, and 6C. PCV13 serotypes represented 65% of the pneumococci isolated from <2 year olds, 71% of 2-4 year olds, 61% of 5-14 year olds, 60% of 15-49 year olds, 53% of 50-64 year olds, and 49% of the ≥65 year olds. Continued monitoring of invasive pneumococcal serotypes in Canada is important to identify epidemiological trends and assess the impact of the newly introduced PCV13 vaccine on public health.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22827750     DOI: 10.1139/w2012-073

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  7 in total

1.  Clinical features and outcomes of serotype 19A invasive pneumococcal disease in Calgary, Alberta.

Authors:  Leah J Ricketson; Otto G Vanderkooi; Melissa L Wood; Jenine Leal; James D Kellner
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-03       Impact factor: 2.471

2.  Statement on the Use of Conjugate Pneumococcal Vaccine - 13 Valent in Adults (Pneu-C-13): An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  C Quach-Thanh; Ms H Thomas
Journal:  Can Commun Dis Rep       Date:  2013-10-30

3.  Phenotypic and molecular characterization of optochin-resistant Streptococcus pneumoniae isolates from Brazil, with description of five novel mutations in the ATPC gene.

Authors:  Tatiana C A Pinto; Aline R V Souza; Sandrine E C M de Pina; Natália S Costa; Armando A Borges Neto; Felipe P G Neves; Vânia L C Merquior; Cícero A G Dias; José M Peralta; Lúcia M Teixeira
Journal:  J Clin Microbiol       Date:  2013-07-24       Impact factor: 5.948

4.  The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019.

Authors:  Eiman Mokaddas; Shabeera Syed; M John Albert
Journal:  Hum Vaccin Immunother       Date:  2021-08-26       Impact factor: 4.526

Review 5.  Composition and immunological significance of the upper respiratory tract microbiota.

Authors:  Louis Patrick Schenck; Michael G Surette; Dawn M E Bowdish
Journal:  FEBS Lett       Date:  2016-11-01       Impact factor: 4.124

6.  The majority of adult pneumococcal invasive infections in Portugal are still potentially vaccine preventable in spite of significant declines of serotypes 1 and 5.

Authors:  Andreia N Horácio; Jorge Diamantino-Miranda; Sandra I Aguiar; Mário Ramirez; José Melo-Cristino
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

7.  Theory and strategy for Pneumococcal vaccines in the elderly.

Authors:  Ho Namkoong; Makoto Ishii; Yohei Funatsu; Yoshifumi Kimizuka; Kazuma Yagi; Takahiro Asami; Takanori Asakura; Shoji Suzuki; Testuro Kamo; Hiroshi Fujiwara; Sadatomo Tasaka; Tomoko Betsuyaku; Naoki Hasegawa
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.